Anti-Mouse CD27 Antibody (RM27-3E5)
Anti-Mouse CD27 Antibody (RM27-3E5) is an agonistic rat-derived IgG2a κ type antibody, targeting to mouse CD27. Anti-Mouse CD27 Antibody (RM27-3E5) stimulates CD 27. Anti-Mouse CD27 Antibody (RM27-3E5) can be used for the researches of cancer and immunology, such as B16cOVA tumor.
For research use only. We do not sell to patients.
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Rat IgG2a kappa
Mouse
CD27
The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Anti-Mouse CD27 Antibody (RM27-3E5) (100 μg, i.p., at days 5, 8, and 11) enhances cytotoxic T lymphocytes response and antitumor immunity companied with anti-CTLA-4/anti-PD-1 in TC-1 tumor mice models[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:B16cOVA/B16F1 experimental metastases mice models[1]
-
Dosage:100 μg
-
Administration:Intraperitoneally injection, every 3-4 days from day 7
-
Result:Reduced tumor nodules.
Increased the proportion of OVA257-specific CD8+ T cells.
Increased IFNγ-expressing cells.
Enhanced or sustained IFNγ-production by tumor infiltrating CD8+ T cells and NK1.1+ cells.
Reduced the proportion of FoxP3+ CD4+ T cells.
-
Animal Model:TC-1 tumor mice models[2]
-
Dosage:100 μg
-
Administration:Intraperitoneally injection, daily, companied with anti-CTLA-4/anti-PD-1
-
Result:Improved cytotoxic T lymphocytes priming and prolonged survival.
Increased cytotoxic T lymphocytes numbers.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
in vivo CD27 stimulation; in vitro CD27 stimulation; Immunoprecipitation; Flow cytometry
Chemical Information
-
Molecular Weight 150 kDa
-
SMILES
[Anti-Mouse CD27 Antibody (RM27-3E5)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Roberts DJ, et al. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. J Immunother. 2010 Oct;33(8):769-79. [Content Brief]
[2]. Ahrends T, et al. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination. Cancer Res. 2016 May 15;76(10):2921-31. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse CD27 Antibody (RM27-3E5) Related Classifications
HY-P990280 Related Classifications
Powered by Bioz